28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
24 Jul
 
Først så tager skattevæsenet  halvdelen af din indkomst.  - Så tager banken 200 kr i kurtage (Udenla..
38
27 Jul
 
  Indledning Over sommeren har jeg læst adskillige bøger om aktier og investering, som har givet mig..
30
24 Jul
 
Til gengæld er operation ved sygdom gratis....Hvis du overlever ventetiden.   Til gengæld kan du som..
28
27 Jul
 
Tese Toneangivende vestlige lande er på vej i fuld fart i retning mod ekspansiv finanspolitik. Dette..
27
28 Jul
 
Det er nu to døgn + ca. 3 timer siden du sidst oprettede en tråd, stillede det samme spørgsmål vedr...
15
28 Jul
GEN
På mange måder ligger Genmab lige nu (kort sigt) i et "alting kan ske" område. Overordnet set ligger..
14
27 Jul
VELO
Og flyt så - for en tid - fokus hen på "ejerne" af Veloxis Pharmaceuticals. Især den ene - NOVO A/S ..
14
24 Jul
 
ER DET IKKE FEDT AT BO I ET LAND SOM DANMARK, uanset hvor meget I brokker jer over det ene eller and..
14
28 Jul
FING-B
Når man ikke tænker i analyser: Deværre tror jeg ikke, at kursen for FPC bliver stabil, så længe der..
13
24 Jul
 
Jeg kender et par stykker som er flyttet til USA (og også et par stykker i Tyskland). Deres rådighed..
13

Form 8.3 - Anheuser-Busch InBev SA/NV

29/07/2016 15:25:24
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

PayPoint plc : Director/PDMR Shareholding

29/07/2016 13:19:43
29 July 2016 PayPoint plc ("the Company") As a result of transactions on 29 July 2016 by the PayPoint plc Share Incentive Plan (a HM Revenue & Customs..

Statement re Amendment to Official List, Share Consolidation and Total Voting Rights

29/07/2016 10:00:21
Intermediate Capital Group plc (the "Company") 29 July 2016 Amendment to Official List, Share Consolidation and Total Voting Rights Further to the ap..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SOCIETE GENERALE: THE EBA PUBLISHES THE RESULTS OF THE 2016 EUROPEAN STRESS TESTING EXERCISE
2
Sanofi : Online Availability of Sanofi Group's Half-Year Financial Report for 2016
3
CREDIT AGRICOLE SA : Crédit Agricole Group's financial robustness confirmed by the 2016 stress test results
4
OP Financial Group's capital adequacy remains solid in the stress test by the European Banking Authority
5
Banco Comercial Português, S.A., informs about Consolidated Earnings of 1st Half 2016

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
30 July 2016 10:10:06
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160728.2 - EUROWEB3 - 2016-07-30 11:10:06 - 2016-07-30 10:10:06 - 1000 - Website: OKAY